MO464: Long-Term Renal Outcomes After ST-Elevation Myocardial Infarction Treated by Percutaneaous Coronary Intervention
Authors: Legras Marie , Amaz Camille , Bochaton Thomas , Mewton Nathan , Soulage Christophe , Guebre-Egziabher Fitsum 
Published: May 2022

Abstract

BACKGROUND AND AIMS
Among patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), short- and long-term renal function evaluations are of prime importance. Most studies have focused on short-term renal dysfunction and acute kidney injury (AKI) occurrence after STEMI treated by PCI, which is associated with major adverse cardiovascular events (MACE) and especially the occurrence of heart failure. However, few studies have focused on long-term renal outcomes.
We aimed to describe renal function evolution and to determine predictors of estimated glomerular filtration rate (eGFR) decline one year after STEMI is treated by PCI.

METHOD
From May 2016 to July 2020, 322 consecutive patients with STEMI who underwent PCI revascularization were enrolled prospectively.
Serum creatinine (SCr) concentration was routinely measured at patient admission, after 48 h or hospital discharge, then during systematic 1-month and 1-year clinical check-ups, AKI was determined according to the Acute Kidney Injury Network (AKIN) definition. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula. The evolution of renal function was evaluated by the difference between admission and 1-month or 1-year eGFR. Rapid progression was defined as a decline in eGFR of more than 5 mL/min/1.73m² per year. Determinants of eGFR decline ≥ 10 mL/min/1.73m² per year were analyzed with multivariate logistic regressions.

RESULTS
The mean age was 59.6 years, 29.5% of patients had a medical history of hypertension, 13.8% had diabetes and 52.8% presented with anterior myocardial infarction. Median admission SCr concentration was 71 µmol/L, with an eGFR of 96.5 mL/min/1.73m² [inter quartile range (IQR): 84.4–105.1]. A total of 38 patients (11.8%) developed AKI.
In the whole population median eGFR decline was 7.7 mL/min/1.73 m² (1.2–14.4) and 8 mL/min/1.73 m² [1.3–15.9] 1-month and 1-year after STEMI respectively (Figure 1). Rapid eGFR decline was found in 59.7% of the total population and 44.6% of patients presented a 1-year eGFR decline of at least 10 mL/min/1.73 m². AKI patients had significant lower eGFR at 1-month and 1-year follow up (median 1-year eGFR of 74.5 mL/min/1.73m² (52.4–96.4) versus 88.1 mL/min/1.73m² (74.0–100.3) in non-AKI patients, P = 0.01). There was no significant difference between AKI and non-AKI patients regarding rates of eGFR decline at both 1-month and 1-year after inclusion.
Multivariate analysis (Table 1) showed that age and 1-month eGFR decline was significantly associated with 1-year eGFR decline ≥ 10 mL/min/1.73m². Especially, 1-month eGFR decline greater than 10 mL/min/1.73m² was an independent and stratified predictor of 1-year eGFR decline with an odds ratio (OR) of 7.45 [95% confidence interval (CI): 2.76–22.81, P &lt; 0.01). AKI occurrence and peak hs-I troponin were not found as predictors of 1-year eGFR decline.

CONCLUSION
Among STEMI patients treated by PCI, a large majority of patients present a significant decline in renal function 1-year after STEMI, regardless of AKI occurrence or infarct size. One-month eGFR decline is a strong predictor of 1-year eGFR evolution and could help identify high-risk patients and adjust nephrological care. Our findings bear important clinical implications and underline the need for longitudinal follow-up of renal function after STEMI is treated by PCI.